Terminated PHASE1 INTERVENTIONAL 1-arm NCT00972023

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer

Sponsor: Barbara Ann Karmanos Cancer Institute

Updated 6 times since 2017 Last updated: Sep 6, 2019 Started: Feb 28, 2010 Primary completion: Mar 31, 2010 Completion: Aug 22, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Barbara Ann Karmanos Cancer Institute

See all terminations from Barbara Ann Karmanos Cancer Institute

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT00972023, this PHASE1 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Barbara Ann Karmanos Cancer Institute, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Oct 2019 — Jan 2021 [monthly]

Terminated PHASE1
Jun 2018 — Oct 2019 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Detroit, United States